Long‐term follow‐up of fixed low‐dose oral immunotherapy for children with severe cow’s milk allergy
Yoko Miura, Ken‐ichi Nagakura, Makoto Nishino, Mari Takei, Kyohei Takahashi, Tomoyuki Asaumi, Kiyotake Ogura, Sakura Sato, Motohiro Ebisawa, Noriyuki Yanagida
Abstract
Abstract Background The efficacy and safety of cow's milk (CM) low‐dose oral immunotherapy (LOIT) at one‐year follow‐up have been previously reported. We investigated the outcome of fixed long‐term LOIT in children with severe CM allergy. Methods Children with positive reactions to oral food challenge (OFC) with 3 mL CM were included. The LOIT group (n = 33) ingested up to 3 mL CM for 1 year. After a two‐week CM avoidance, 3 and 25 mL OFCs were performed. Children with positive reactions continued with 3 mL ingestion, with OFCs repeated yearly. Regular home consumption of 25 mL CM after passing the OFCs was defined as 25 mL short‐term unresponsiveness (25 mL STU). The historical control group (n = 16) with reactions to 3 mL OFC eliminated daily CM ingestion. Results The proportion of 25 mL STU in the LOIT group was 27%, 52%, and 61% after 1, 2, and 3 years, respectively, and the 3‐year percentage was significantly higher than that in the historical control group (13%, P = .002). In the LOIT group, only one child developed severe symptoms. Furthermore, in this group, CM‐ and casein‐specific immunoglobulin E (sIgE) levels decreased significantly and casein‐specific IgG and IgG 4 levels increased significantly after 3 years, whereas the historical control group presented no significant change in these parameters. Baseline sIgE levels were significantly low in children achieving 25 mL STU. Conclusion Continued fixed LOIT yields immunologic improvement and may be effective and safe for severe CM allergy.